Genus plc
Genus plc (GENSF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
gensf · pe ratio · data through Jun 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Genus plc (GENSF) measures how much investors pay for each dollar of the company's trailing earnings. GENSF's current PE ratio of 31.11x is calculated by dividing its stock price of $35.00 by its TTM earnings per share of $0.72. −57.9% discount vs 5Y avg 73.9x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-06-30
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%28.8x
MedianQ3 · 75%221.6x
Max
At 31.11x, GENSF's current P/E is within its average historical range over the past 20 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Genus plcYou GENSF | $2.3B | 31.11x | -18.2% | $0.72 |
 Bonesupport Holding AB (publ) BOEUF | $1.6B | 84.78x | +123.0% | $2.15 |
 BioArctic AB (publ) BRCTF | $3.1B | 27.80x | -26.9% | $11.52 |
 CStone Pharmaceuticals CSPHF | $1.1B | N/A | — | -$0.31 |
 Gerresheimer AG GRRMF | $1.1B | 23.31x | -38.7% | $3.18 |
 Green Thumb Industries Inc. GTBIF | $2.0B | 16.19x | -57.4% | $0.50 |
 Mesoblast Limited MEOBF | $2.0B | N/A | — | -$0.08 |
Industry Average 4 peers with valid PE | — | 38.02x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-06-30Latest FY2025 | 64.70x | $0.29 | -53.4% | |
2024-06-30 FY2024 | 138.89x | $0.12 | +155.0% | |
2023-06-30 FY2023 | 54.46x | $0.51 | +38.2% | |
2022-06-30 FY2022 | 39.39x | $0.63 | -45.4% | |
2021-06-30 FY2021 | 72.16x | $0.73 | +57.0% | |
2020-06-30 FY2020 | 45.96x | $0.54 | -79.3% | |
2019-06-30 FY2019 | 221.58x | $0.12 | +483.0% | |
2018-06-30 FY2018 | 38.01x | $0.70 | +18.3% | |
2017-06-30 FY2017 | 32.12x | $0.54 | +73.9% | |
2016-06-30 FY2016 | 18.47x | $0.81 | -9.7% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Genus plc (GENSF) measures how much investors pay for each dollar of the company's trailing earnings. GENSF's current PE ratio of 31.11x is calculated by dividing its stock price of $35.00 by its TTM earnings per share of $0.72.
Frequently asked questions
GENSF pe ratio · 6 questionsGENSF's current PE ratio is 31.11x as of 2026-06-08, based on a stock price of $35.00 and TTM EPS of $0.72. Data sourced from Financial Modeling Prep via GENSF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Genus plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08